argenx SE Share Price & Technical Analysis
ARGX · $800.9 (-0.69%)
Healthcare / Biotechnology
$800.9
-0.69%
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develop…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
3% return in May, -4% avg return in past 3 year May month.
-4% return in 2026, 29% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | -9% | -4% | 5% | 3% | – | – | – | – | – | – | – | -4% |
| 25 | 5% | -5% | -8% | 9% | -11% | -4% | 21% | 6% | 4% | 5% | 12% | -7% | 28% |
| 24 | 1% | 0% | 4% | -5% | -1% | 16% | 20% | 2% | 6% | 8% | 4% | 0% | 54% |
| 23 | 0% | -4% | 1% | 6% | 0% | 0% | 30% | -1% | -5% | -4% | -5% | -16% | 3% |
| 22 | -23% | 7% | 7% | -9% | 8% | 20% | -2% | 5% | -4% | 8% | 2% | -6% | 12% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$51.50B
P/E ratio
36.56
52W high
$934.6
52W low
$510.1
Volume
16,635
Beta
-0.06
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is argenx SE share price today?
- argenx SE (ARGX) last traded around $800.9 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ARGX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ARGX. Download the app for real-time alerts.
- How can I analyze argenx SE stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.